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Abstract
Background/Aim. Hepatitis C virus (HCV) infection is an
important sociomedical problem worldwide because the
chronification of the disease is frequent and the occurance of
liver cirrhosis and hepatocellular carcinoma can be expected.
The aim of this study was to determine the way of infection,
pathohistological changes of the liver, virus genotype presence
and sustained virological response after pegylated interferon
and ribavirin therapy in prison inmates. Methods. The study
included 52 patients with chronic HCV infection classified in
two groups managed during 2008–2010. The first group con-
sisted of prisoners (n = 22) and the second one of “non-
prisoners” (n = 30). The patients from both groups underwent
diagnostic preparation (biochemical analyses, liver biopsy,
hepatitis virus detection and genotypisation using polymerase
chain reaction issue). The treatment lasted for 24 weeks for vi-
rus genotypes 2 and 3, and 48 weeks for genotypes 1 and 4.
Results. All the patients were males, approximately the same
age (35 ± 4.1 and 31 ± 7.6 years). Virus genotype 1 was signifi-
cantly more frequent in the prisoners (p < 0.05), that demanded
longer treatment (48 weeks). At the same time, statistically sig-
nificant higher number of patients, “non-prisoners”, achieved a
sustained virological response (p < 0.01). Conclusion. Intrave-
nous drug abuse and tattoos, separately or together, are the
most frequent way of infection in prisoners. The dominant
presence of virus genotype 1 resulted in lower number of pa-
tients with sustained virological response, probably regardless
prison environment and regime.
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Apstrakt
Uvod/Cilj. Hepatitis C virus (HCV) infekcija je važan soci-
omedicinski problem širom sveta zbog ÿeste hronizacije
bolesti kao i pojave ciroze jetre i hepatocelularnog karcino-
ma. Cilj rada bio je da se utvrdi put širenja infekcije, patohi-
stološke promene jetre, genotipska zastupljenost virusa i
stabilni virusološki odgovor na unos pegilovanog interfero-
na i ribavirina kod zatvorenika. Metode. Ispitivanjem su
bila obuhvaýena 52 bolesnika sa hroniÿnom HCV infekci-
jom, leÿena u periodu 2008–2010, podeljena u dve grupe.
Prvu grupu ÿinili su zatvorenici (n = 22), a drugu „ne-
zatvorenici“ (n = 30). Svi bolesnici su prethodno bili podvr-
gnuti dijagnostiÿkoj pripremi (biohemijska obrada, biopsija
jetre, ispitivanje prisustva virusa reakcijom lanÿane polimeri-
zacije i genotipsko sagledavanje). Leÿenje je sprovedeno to-
kom 24 nedelje za genotip virusa 2 i 3, i tokom 48 nedelja za
genotip 1 i 4. Rezultati. Svi ispitanici su bili muškog pola,
približno iste starosti (35 ± 4.1, odnosno 31 ± 7.6 godina).
Dobijeni rezultati pokazuju statistiÿki znaÿajno ÿešýu prisut-
nost genotipa 1 kod zatvorenika (p < 0.05), što je zahtevalo
duže leÿenje (48 nedelja). Istovremeno je zapaženo da je
statistiÿki znaÿajno veýi broj „ne-zatvorenika“, postigao sta-
bilni virusološki odgovor (p < 0.01). Zakljuÿak. Intraven-
ska narkomanija i tetovaža, pojedinaÿno ili udruženo, najÿe-
šýi su naÿin infekcije kod zatvorenika. Dominantna prisut-
nost genotipa 1 imala je za rezultat niži broj bolesnika sa
stabilnim virusološkim odgovorom, verovatno nezavisno od
sredine boravka i režima života.
Kljuÿne reÿi:
hepatitis C; zatvorenici; genotip; infekcija; faktori
rizika; leÿenje, ishod.
Introduction
Hepatitis C virus (HCV) infection is an important so-
ciomedical problem worldwide. The importance of acute
HCV is reflected in a high percentage of the disease chroni-
fication (65–80%), or the occurrence of liver cirrhosis (10–
20%) and a possible development of hepatocellular
carcinoma in 1–5% of people with liver cirrhosis 
1, 2. There
are approximately 200 million people with HCV infection
today, which is somewhere around 3% of the world popula-
tion. HCV infection is widespread worldwide, with some
specificity in genotypic localization observed. Particularly,
North America is characterized by the presence of virus
genotype 1a, which predominates, followed by genotypes 2a,Volumen 70, Broj 11 VOJNOSANITETSKI PREGLED Strana 1007
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2b and 3a. The dominant genotype in Europe is 1b, followed
by 2a, 2b, 2c and 3a. In Africa dominate genotypes are 4 and
5 
3, 4. The prevalence of HCV infection among general
population is uneven, with higher prevalence in southern
Europe 
4. High prevalence of HCV infection was observed in
Egypt (20%) and it is explained by the treatment of schisto-
somiasis 
5. Ways of getting a HCV infection are various.
However, studies show that the infection is mostly transmit-
ted by intravenous heroin use, exposure to blood and blood
derivatives, nasal drug use, from sexually active persons
(promiscuous persons), tattoos, piercing, etc. 
1, 6. Intravenous
drug users are at higher risk for blood transmissible diseases
(human immunodeficiency virus (HIV), HCV, hepatitis B vi-
rus and other). This problem is being significantly potenti-
ated in persons who are housed in prisons. Specifically,
among the general population in the United States the
prevalence of HCV infection ranges from 1% to 2% and the
proportion is significantly higher, up to 80%, in imprisoned
adults who are intravenous drug addicts. Studies show that
among prisoners 17.6% are intravenous drug users, 56.1%
use drugs intranasally, 56% have various tattoos and 39.6%
have a history of variety injection equipment use 
7. All of
these activities contribute to the significant number of blood
transmitted diseases among this population. HCV infection
incidence is different in prisons around the world, ranging
from 25% to 40% 
8–11. In a certain number of inmates HBV
and HIV coinfection can be seen 
12.
A relatively small percentage of persons with chronic
HCV, in the Correctional Prison (KPZ) in Niš, are submitted
to disease examination or treatment by modern standards. A
modern therapeutic approach to these patients is identical to
general population. The persons with virus genotypes 1 and 4
are treated during 48 weeks with pegylated interferon alpha-
2a at a dose of 180 mg once weekly and daily intake of riba-
virin at a dose of 1,000–1,200 mg 
13. The patients with HCV
genotypes 2 and 3 have shorter treatment, 16 or 24 weeks
with the same dose of pegylated interferon alfa-2a and riba-
virin in a dose of 800 mg daily 
14, 15. This treatment provides
a different percentage of sustained virological response
(SVR), in genotypes 2 and 3 the percentage is about 80%,
while in the patients with genotypes 1 and 4, SVR achieve-
ment is around 50% 
16.
The aim of this study was to examine treatment possi-
bilities in this marginalized group of people, to find the most
common way of infection in the group, genotypic represen-
tation and also to assess therapeutic effects of pegylated in-
terferon alpha-2a combined with ribavirin.
Methods
The study involved 52 patients with chronic HCV in-
fection, during 2008–2010. All the subjects were males, born
between 1966 and 1985, and divided into two groups. The
first group consisted of imprisoned patients, thus that re-
ceived their treatment in prisons (n = 22), the second (con-
trol) group comprised ”non-prisoners” (n = 30), randomly
included patients from the Clinic for Infectious Diseases in
Niš. The prisoners were mostly from the KPZ in Niš (n =
15), some were from the KPZ in Leskovac (n = 6), and one
(n = 1) was serving his turn in Vranje. A number of impris-
oned patients started their treatment in prisons (n = 17),
while others had already received their treatment before
coming to prison (n = 5). In forming the second group, the
approach was discriminant, female patients were eliminated
since all the prisoners were male. Also, intentionally both
patients groups were approximately the same age.
Using epidemiological analysis we found that some
subjects, from both groups, had a history of intravenous drug
abuse, so they had to gain psychiatric conformation of being
abstinent for more than 6 months. Examining the imprisoned
patients we saw extensive tattoos that were made during stay
in KPZ. The prisoners had in their files different crimes
committed, ranging from theft, robbery and murders. During
examination all the prisoners were escorted by the police of-
ficers.
All the patients were tested for HIV infection (n = 0) and
hepatitis B infection (n = 0). Shortly before starting the antivi-
ral therapy, prisoners underwent hospital preparation: bio-
chemical analyses, upper abdomen ultrasound, liver biopsy,
and detection of the virus and its genotype, by the polymerase
chain reaction (PCR) assay (Amplicor Monitor Assay; Roche
Molecular Systems, Branchburg, NJ 08876, USA). Pathohis-
tological examination of liver biopsy specimens was done at
the Pathology Institute, Clinical Center in Niš. PCR and
genotypisation were done at the Institute for Infectious and
Tropical Diseases in Belgrade. The patients with virus geno-
types 1 and 4 received pegylated interferon at a dose of 180
mg subcutaneously, once a week for 48 weeks, plus ribavirin
at a daily dose of 1,000–1,200 mg per os; while patients with
virus genotypes 2 and 3 received the same dose of pegylated
interferon but ribavirin in a dose of 800 mg daily for 24
weeks. The prisoners’ therapy was carried out almost with-
out interruption, except in one period of 7 days, when there
was a riot in the KPZ Niš. During the therapy the patients
were tested for products of heroin degradation, which were
found in only one patient (KPZ Leskovac), and so his treat-
ment had to be discontinued after seven months. We should
also point out a correct laboratory monitoring of the patients
during the therapy, by both prisons’ physicians. Namely,
regular monitoring of blood work values was performed, that
provided a possibility for medications doses correction. Both
groups were followed up on the basis of selected parameters
in order to detect some possible features that would be spe-
cific for the group.
Data were analyzed by the standard descriptive methods:
arithmetic mean and standard deviation (ʉ ± SD). To deter-
mine a statistical significance the Student’s t-test was used; the
level of probability (p) < 0.05 was considered statistically sig-
nificant. Analysis was done using Microsoft Office Excel 2003
software package in Windows XP Professional environment.
Results
The average age of prisoners was 35 ± 4.1 (ʉ ± SD)
years, while the average age of the patients in the group II
was 31 ± 7.6 years. Tables 1–4 show their characteristics.Strana 1008 VOJNOSANITETSKI PREGLED Volumen 70, Broj 11
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Table 1
The way of hepatitis C virus infection in the patients
Group of patients Way of infection Prisoners [n (%)] Non-prisoners [n (%)] Total [n (%)]
Intravenous 9 (40.9) 7 (23.3) 16 (30.7)
Unknown 2 (9.1) 10 (33.4) 12 (23.1)
Tatoo 3 (13.6) 4 (13.3) 7 (13.5)
Tatoo + intravenous 6 (27.3) 5 (16.7) 11 (21.2)
Else 2 (9.1) 4 (11.5) 6 (11.5)
Total 22 (100) 30 (100) 52 (100)
Table 2
The genotypes of hepatitis C virus among the patients
Groups of patients Genotypes
of the virus Prisoners  [n (%)] Non-prisoners  [n (%)] Total [n (%)]
1 14 (63.7) 9 (30) 23 (44.2)
1 + 4 3 (13.6) 1 (3.3) 4 (7.8)
2 0 (0) 1 (3.3) 1 (1.9)
3 4 (18.2) 19 (63.4) 23 (44.2)
1 + 2 1 (4.5) 0 (0) 1 (1.9)
Total 22 (100) 30 (100) 52 (100)
Table 3
The liver fibrosis level in the patients
Groups of patients Fibrosis
score* Prisoners [n (%)] Non-prisoners [n (%)] Total [n (%)]
F0 2 (9.1) 3 (10) 5 (9.6)
F1 11 (50) 10 (33.3) 21 (40.4)
F2 8 (36.4) 9 (30) 17 (32.7)
F3 1 (4.5) 7 (23.3) 8 (15.4)
F4 0 (0) 1 (3.3) 1 (1.9)
Total 22 (100) 30 (100) 52 (100)
*Histopathological findings from liver biopsy; F0 –no fibrosis (normal liver); F1 – mild fibrosis;
F2 – moderate fibrosis; F4 – cirrhosis.
Table 4
Virological response in the patients after the therapy
Groups of patients Virological
response Prisoners [n (%)] Non-prisoners [n (%)] Total [n (%)]
Sustained 13 (59.1) 25 (83.3) 38 (73.1)
Unsustainable 8 (36.4) 5 (16.7) 13 (25.0)
Undefinied* 1 (4.5) 0 (0) 1 (1.9)
Total 22 (100) 30 (100) 52 (100)
*The therapy cessation in one patient.
Comparison of the viral ribonucleic acid (RNA) copies
number in blood showed that the number of patients with less
than one million copies of HCV-RNA was significantly higher
among prisoners (p < 0.05). There were no other significant dif-
ferences in the number of HCV-RNA copies (Figure 1). Also,
we did not find any significant difference in the way of infection
between the groups of patients, as well as any significant differ-
ence in histopathologic findings of the liver. A significantly
higher number of patients in the prisoners’ group had HCV
genotype 1 (p < 0.05), while the greater number of patients in
the control group was infected with virus genotype 3 (p < 0.01).
We also found a significant difference between the two
groups of patients in the treatment duration (48 or 24 weeks).
That is, a significantly higher number of prisoners were treated
48 weeks, while in the control group a significantly higher
number of patients were treated for 24 weeks (p < 0.01).
Also, a significantly higher number of patients in the
control group achieved SVR (p < 0.01).
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Fig. 1 – The patients groups percentage ratio according to
hepatitis C virus ribonucleic acid (HCV-RNA) viral copies in
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Discussion
Comparison of the subjects in the groups I and II, based
on the obtained statistical data, allowed us to determine some
characteristics in the treatment of this marginalized population.
The patients of the group I noted in their histories intravenous
drug use, alone or associated with tattoos, as the transmission
route of HCV infection, but this was encountered even in the
patients of the group II in few cases. This observation is con-
sistent with findings obtained by other authors 
1, 6. In the con-
trol group a significant number of patients was not able to re-
call any event that could be the source of infection, and this
was labeled as an unknown way of transmission, which is also
seen frequently. We also noted significant differences in the
distribution of HCV genotypes between the groups. HCV
genotype 1 was the most common genotype in the group I
subjects, whereas genotype 3 was the most frequent in the
control group. Such distribution of genetic background influ-
ences the implementation (duration) of the treatment, and there
was a significant difference in the treatment duration among
the examined groups (p < 0.01). At the same time differences
in the level of SVR was noted. Namely, it is well- known that
patients with chronic HCV genotype 1 achieve SVR in a sig-
nificantly lower percentage (50%) than patients with other
genotypes 
16, whereas patients infected with HCV genotype 2
or 3 have a significantly higher percentage of SVR (80%) 
16.
This distribution of genotypes explains the difference in treat-
ment length between the groups. Among the subjects of the
group I there was not a single registered case of HBV nor HIV
coinfection, which can be found in the allegations made by
other authors 
12. This may be explained to some extent by a
small number of participants in the study. Although, the avail-
able knowledge suggests that HBV and HIV co-infection can
be encountered among the prisoners sent to the Clinic for In-
fectious Diseases in Niš, these patients were not present in our
study. The treatment was discontinued in one patient because
of the presence of heroin traces, after seven months of treat-
ment, during a routine screening of all inmates undergoing an-
tiviral treatment. This method of monitoring for the drug traces
in urine allows us, among other things, the elimination of her-
oin-returnees from the treatment. However, a question remains
how this inmate got heroin while being in prison?
Conclusion
Intravenous drug abuse, alone or associated with tattoos, is
the most common way of infection in the prisoners. HCV
genotype 1 is predominant in the prisoners while HCV genotype
3 is the most frequent in the non-prisoners. There were no sig-
nificant differences among the patients groups in terms of viral
load (HCV-RNA copies number), but more patients with viral
load below million copies were in the prisoners group (p <
0.05). Significantly greater number of the control group patients
achieved SVR due to the viral genotype differences.
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